bioAffinity Technologies, Inc. — Form 8-K
Filed October 13, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 28/100
What the filing says
bioAffinity Technologies announced it will present research data at the October 2026 CHEST conference on a sputum-based test in development to measure lung inflammation biomarkers and biologic drug targets in asthma and COPD patients. The test uses the company's proprietary flow cytometry + AI platform (same foundation as its commercial CyPath Lung cancer diagnostic) and can detect multiple inflammatory markers including TSLP, CRLF2, IL4-R, and IL-5 that are targeted by approved biologic therapies. No specific financial figures, partnership announcements, or clinical trial results with quantified efficacy data are disclosed; this is a research presentation announcement only.
Why this rating
Early-stage R&D milestone (conference poster) for pre-commercial test; no revenue, partnership, or validated clinical data. Addresses $22.6M market-cap company's pipeline expansion but remains investigational with no timeline or commercialization commitment.
See more from October 13, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.